 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Gerodorm 40mg |
| AHFS/Drugs.com | cinolazepam |
| Dependence liability | High |
| Addiction liability | Medium |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 90–100% |
| Metabolism | Hepatic |
| Onset of action | 30 minutes to 1 hour |
| Eliminationhalf-life | 9 hours |
| Duration of action | 9 hours |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C18H13ClFN3O2 |
| Molar mass | 357.77 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
 N Y (what is this?) (verify) | |
Cinolazepam[1] (marketed under the brand nameGerodorm)[2] is a drug which is abenzodiazepine derivative. It possessesanxiolytic,anticonvulsant,sedative andskeletal muscle relaxant properties.Due to its strong sedative properties, it is primarily used as ahypnotic.
It was patented in 1978 and came into medical use in 1992.[3] Cinolazepam is mainly used in Romania and Slovakia; it not approved for sale in the United States or Canada.
